Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Nicholas P. Tschernia, MD, Vaibhav Kumar, MBBS,MS, Dominic T. Moore, MPH, MS, Benjamin G. Vincent, MD, Callie C. Coombs, MD, Hendrik Van Deventer, MD, Matthew C. Foster, MD, Amy E. DeZern, MD, Leo Luznik, MD, Marcie L. Riches, MDMS, Jonathan S. Serody, MD, Ivana Gojo, MD, Joshua F. Zeidner, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-138786

Published: 2020

Journal Articles

High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant - a Single Center Experience

Timothy J Voorhees, MD, Natalie S Grover, MD, Jonathan Galeotti, MD MS, Nathan D Montgomery, MD, Dominic T. Moore, MPH, MS, Anne Beaven, MD, Christopher Dittus, DO

Blood (2019) 134 (Supplement_1): 2915.

https://doi.org/10.1182/blood-2019-126228

Published: 2019

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

Journal Articles

Class I HLA Peptide Epitope Binding Efficiency Has No Impact on Graft Vs. Host Disease Incidence Following Allogeneic Hematopoietic Cell Transplantation

Charlotte McIlwaine Story, BS, MD, Jefferson L. Lansford, BS, Dominic T. Moore, MPH, MS, Chang Xu, Benjamin G. Vincent, MD, Paul M. Armistead, MD PhD, Marcie L. Riches, MDMS

Blood (2017) 130 (Supplement 1): 1987.

https://doi.org/10.1182/blood.V130.Suppl_1.1987.1987

Published: 2017

Journal Articles

Mitoxantrone and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplant for Multiple Myeloma.

Anne W. Beaven, MD, Terrance Comeau, MD, Andrew Sharf, RN, Dominic T. Moore, MPH, Jonathan Serody, MD, PhD, Thomas C. Shea, MD, Don A. Gabriel, MD, PhD

Blood (2006) 108 (11): 2945.

https://doi.org/10.1182/blood.V108.11.2945.2945

Published: 2006

NARROW

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant - a Single Center Experience

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Class I HLA Peptide Epitope Binding Efficiency Has No Impact on Graft Vs. Host Disease Incidence Following Allogeneic Hematopoietic Cell Transplantation

Mitoxantrone and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplant for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant - a Single Center Experience

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Class I HLA Peptide Epitope Binding Efficiency Has No Impact on Graft Vs. Host Disease Incidence Following Allogeneic Hematopoietic Cell Transplantation

Mitoxantrone and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplant for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only